MA34221B1 - Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs - Google Patents
Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeursInfo
- Publication number
- MA34221B1 MA34221B1 MA35354A MA35354A MA34221B1 MA 34221 B1 MA34221 B1 MA 34221B1 MA 35354 A MA35354 A MA 35354A MA 35354 A MA35354 A MA 35354A MA 34221 B1 MA34221 B1 MA 34221B1
- Authority
- MA
- Morocco
- Prior art keywords
- robo1
- fusion protein
- tumor treatment
- protein
- relates
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Abstract
La présente invention concerne une protéine recombinante Robo1-Fc et son utilisation pour traiter les maladies dans lesquelles une protéine Slit est surexprimée, en particulier le cancer. Elle concerne également une composition comprenant une telle protéine recombinante. Un autre aspect de l'invention consiste en l'utilisation d'une molécule Robo1-Fc en tant qu'outil de diagnostic pour détecter la surexpression d'une molécule de la famille Slit chez un patient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1052829A FR2958936A1 (fr) | 2010-04-14 | 2010-04-14 | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
PCT/FR2011/050811 WO2011128561A1 (fr) | 2010-04-14 | 2011-04-08 | Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34221B1 true MA34221B1 (fr) | 2013-05-02 |
Family
ID=42830780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35354A MA34221B1 (fr) | 2010-04-14 | 2011-04-08 | Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
Country Status (26)
Country | Link |
---|---|
US (1) | US9493529B2 (fr) |
EP (1) | EP2558489A1 (fr) |
JP (1) | JP5858442B2 (fr) |
KR (1) | KR20130059329A (fr) |
CN (1) | CN102884076A (fr) |
AR (1) | AR080891A1 (fr) |
AU (1) | AU2011239839B2 (fr) |
BR (1) | BR112012026020A2 (fr) |
CA (1) | CA2796303A1 (fr) |
CL (1) | CL2012002879A1 (fr) |
CR (1) | CR20120508A (fr) |
DO (1) | DOP2012000265A (fr) |
EA (1) | EA201291044A1 (fr) |
EC (1) | ECSP12012230A (fr) |
FR (1) | FR2958936A1 (fr) |
GT (1) | GT201200275A (fr) |
IL (1) | IL222382A (fr) |
MA (1) | MA34221B1 (fr) |
MX (1) | MX338981B (fr) |
NI (1) | NI201200155A (fr) |
PE (1) | PE20130199A1 (fr) |
SG (1) | SG184529A1 (fr) |
TN (1) | TN2012000473A1 (fr) |
TW (1) | TW201142024A (fr) |
UY (1) | UY33334A (fr) |
WO (1) | WO2011128561A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012085178A1 (fr) * | 2010-12-23 | 2012-06-28 | Sanofi | Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes |
MX351313B (es) | 2012-01-05 | 2017-10-10 | Boston Medical Ct Corp | Señalización de slit-robo para diagnosis y tratamiento de enfermedad del riñón. |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
CN107298715B (zh) * | 2016-04-15 | 2021-05-04 | 阿思科力(苏州)生物科技有限公司 | Slit2D2-嵌合抗原受体及其应用 |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
AU2018278809B2 (en) * | 2017-06-02 | 2022-03-31 | Boston Medical Center Corporation | Recombinant ROBO2 proteins, compositions, methods and uses thereof |
US11406682B2 (en) | 2017-08-24 | 2022-08-09 | Bar-Ilan University | Roundabout (Robo) receptor inhibitors and uses thereof |
CA3136663A1 (fr) * | 2019-04-23 | 2020-10-29 | The Regents Of The University Of California | Compositions et methodes utiles pour favoriser la production de lait |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
AU729496B2 (en) * | 1997-10-20 | 2001-02-01 | Regents Of The University Of California, The | Robo: a novel family of polypeptides and nucleic acids |
NZ507063A (en) * | 1998-04-02 | 2003-11-28 | Rigel Pharmaceuticals Inc | Self-dimerising peptides causing the formation of compact structures |
WO2002010217A2 (fr) * | 2000-08-02 | 2002-02-07 | The Johns Hopkins University | Profils d'expression de cellules endotheliales |
PT1572169E (pt) | 2002-03-08 | 2013-10-08 | Shanghai Inst Biol Sciences | Deteção e modulação da angiogénese mediada pela slit e roundabout (robo), e correspondentes utilizações |
WO2005014818A1 (fr) * | 2003-08-08 | 2005-02-17 | Perseus Proteomics Inc. | Gene surexprime dans le cancer |
CA2553187A1 (fr) * | 2004-01-28 | 2005-08-11 | Syntonix Pharmaceuticals, Inc. | Proteines de fusion heterodimere de l'hormone-fc stimulant les follicules (fsh-fc) utiles dans le traitement de l'infertilite |
KR20140071452A (ko) * | 2006-04-05 | 2014-06-11 | 애브비 바이오테크놀로지 리미티드 | 항체 정제 |
AR063975A1 (es) | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
EP2599791A1 (fr) * | 2007-04-27 | 2013-06-05 | Genentech, Inc. | Anticorps anti-CD4 puissants, stables et non immunosuppresseurs |
UY31309A1 (es) | 2007-08-29 | 2009-03-31 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso | |
EP2050764A1 (fr) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Nouveau format d'anticorps bispécifique polyvalent |
-
2010
- 2010-04-14 FR FR1052829A patent/FR2958936A1/fr active Pending
-
2011
- 2011-04-08 CA CA2796303A patent/CA2796303A1/fr not_active Abandoned
- 2011-04-08 CN CN2011800238283A patent/CN102884076A/zh active Pending
- 2011-04-08 PE PE2012002019A patent/PE20130199A1/es not_active Application Discontinuation
- 2011-04-08 US US13/641,012 patent/US9493529B2/en active Active
- 2011-04-08 AU AU2011239839A patent/AU2011239839B2/en not_active Ceased
- 2011-04-08 JP JP2013504311A patent/JP5858442B2/ja not_active Expired - Fee Related
- 2011-04-08 SG SG2012075107A patent/SG184529A1/en unknown
- 2011-04-08 MA MA35354A patent/MA34221B1/fr unknown
- 2011-04-08 KR KR1020127026724A patent/KR20130059329A/ko not_active Application Discontinuation
- 2011-04-08 EP EP11719346A patent/EP2558489A1/fr not_active Withdrawn
- 2011-04-08 BR BR112012026020A patent/BR112012026020A2/pt not_active IP Right Cessation
- 2011-04-08 MX MX2012011822A patent/MX338981B/es active IP Right Grant
- 2011-04-08 WO PCT/FR2011/050811 patent/WO2011128561A1/fr active Application Filing
- 2011-04-08 EA EA201291044A patent/EA201291044A1/ru unknown
- 2011-04-13 AR ARP110101252A patent/AR080891A1/es unknown
- 2011-04-14 UY UY0001033334A patent/UY33334A/es not_active Application Discontinuation
- 2011-04-14 TW TW100113039A patent/TW201142024A/zh unknown
-
2012
- 2012-09-28 TN TNP2012000473A patent/TN2012000473A1/fr unknown
- 2012-10-05 DO DO2012000265A patent/DOP2012000265A/es unknown
- 2012-10-08 EC ECSP12012230 patent/ECSP12012230A/es unknown
- 2012-10-08 CR CR20120508A patent/CR20120508A/es unknown
- 2012-10-11 GT GT201200275A patent/GT201200275A/es unknown
- 2012-10-11 IL IL222382A patent/IL222382A/en not_active IP Right Cessation
- 2012-10-12 NI NI201200155A patent/NI201200155A/es unknown
- 2012-10-12 CL CL2012002879A patent/CL2012002879A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP5858442B2 (ja) | 2016-02-10 |
MX2012011822A (es) | 2012-11-12 |
CL2012002879A1 (es) | 2013-03-22 |
EP2558489A1 (fr) | 2013-02-20 |
TN2012000473A1 (fr) | 2014-01-30 |
UY33334A (es) | 2011-12-01 |
US9493529B2 (en) | 2016-11-15 |
AR080891A1 (es) | 2012-05-16 |
AU2011239839A1 (en) | 2012-11-08 |
NI201200155A (es) | 2013-02-05 |
JP2013523172A (ja) | 2013-06-17 |
CA2796303A1 (fr) | 2011-10-20 |
DOP2012000265A (es) | 2013-02-28 |
SG184529A1 (en) | 2012-11-29 |
BR112012026020A2 (pt) | 2016-06-28 |
KR20130059329A (ko) | 2013-06-05 |
CR20120508A (es) | 2012-11-01 |
EA201291044A1 (ru) | 2013-04-30 |
US20130039912A1 (en) | 2013-02-14 |
ECSP12012230A (es) | 2012-11-30 |
FR2958936A1 (fr) | 2011-10-21 |
IL222382A0 (en) | 2012-12-31 |
TW201142024A (en) | 2011-12-01 |
IL222382A (en) | 2016-06-30 |
AU2011239839B2 (en) | 2015-08-20 |
CN102884076A (zh) | 2013-01-16 |
WO2011128561A1 (fr) | 2011-10-20 |
MX338981B (es) | 2016-05-06 |
PE20130199A1 (es) | 2013-03-09 |
GT201200275A (es) | 2014-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34221B1 (fr) | Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs | |
WO2008101985A3 (fr) | Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation | |
MY171100A (en) | Anti-ceacam5 antibodies and uses thereof | |
WO2004108139A3 (fr) | Utilisation de composes heterocycliques en tant qu'inhibiteurs de scce | |
EA200970403A1 (ru) | Бициклические триазолы в качестве модуляторов протеинкиназы | |
MA33566B1 (fr) | Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux | |
UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
AU2011338389A8 (en) | Bicyclic compounds as Pim inhibitors | |
NO20055209D0 (no) | Peptabody for cancerbehandling | |
EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
MX2009004038A (es) | Gel de diclofenaco. | |
MX2011010673A (es) | Formulaciones de nanoparticulas y usos de las mismas. | |
WO2010066684A3 (fr) | Inhibiteurs pyridyloxyindoles de vegf-r2 et utilisation thérapeutique de ceux-ci | |
TNSN07093A1 (en) | Bicyclic amides as kinase inhibitors | |
CL2011003052A1 (es) | Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras. | |
WO2009093119A3 (fr) | Utilisation d'inhibiteurs de sérine protéases pour traiter des maladies de peau | |
GEP20125647B (en) | Kinesin inhibitors as cancer therapeutics | |
EP2175879A4 (fr) | Traitement de maladies associées à la protéine prion | |
ATE472998T1 (de) | Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis | |
ATE506961T1 (de) | Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen | |
MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
MA34291B1 (fr) | Compositions et méthodes de diagnostic et de traitement d'une tumeur | |
WO2010036031A3 (fr) | Anticorps monoclonal humain specifique au pauf, composition pharmaceutique destinee au traitement du cancer le comprenant et procede l'utilisant pour detecter le cancer | |
MA37961A1 (fr) | Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation | |
MA34480B1 (fr) | Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires |